{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:52Z","timestamp":1790352532100,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Artemisinin is an antimalarial compound derived from the plant <jats:italic>Artemisia annua<\/jats:italic> L., also known as sweet wormwood. According to the World Health Organization, artemisinin\u2010based combination therapy (ACT) is an essential treatment for malaria, specifically <jats:italic>Plasmodium falciparum<\/jats:italic>, which accounts for most malaria\u2010related mortality. ACTs used to treat uncomplicated malaria include artemether\u2010lumefantrine, artesunate\u2010amodiaquine, artesunate\u2010mefloquine, artesunate\u2010sulphadoxine\u2010pyrimethamine, and dihydroartemisinin\u2010piperaquine. Although the mechanism of action and clinical capabilities of artemisinin in malaria treatment are widely known, more information on the potential for drug interactions needs to be further investigated. Some studies show pharmacokinetic and pharmacodynamic drug interactions with HIV antiviral treatment but few studies have been conducted on most other drug classes. Based on known genotypes of cytochrome P450 (CYP) enzymes, CYP2B6 and CYP3A are primarily involved in the metabolism of artemisinin and its derivatives. Reduced functions in these enzymes can lead to subtherapeutic concentrations of the active metabolite, dihydroartemisinin, that may cause treatment failure, which has been shown in some studies with cardiovascular, antibiotic, and antiparasitic drugs. Although the clinical importance remains unclear to date, clinicians should be aware of potential drug\u2010drug interactions and monitor patients on ACT closely.<\/jats:p>","DOI":"10.1002\/jcph.2073","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T11:24:50Z","timestamp":1652268290000},"page":"1197-1205","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Drug\u2010Drug Interactions of Artemisinin\u2010Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature"],"prefix":"10.1002","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-7968","authenticated-orcid":false,"given":"Joyce","family":"Hernandez Maldonado","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry College of Pharmacy University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2302-8949","authenticated-orcid":false,"given":"Oliver","family":"Grundmann","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry College of Pharmacy University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"WHO.World Malaria Report 2020: 20 Years of Global Progress and Challenges;2020."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-015-4948-7"},{"key":"e_1_2_11_4_1","unstructured":"CDC.U.S President's Malaria Initiative: 13th Annual Report to Congress. Prevention C for DC and ed.https:\/\/www.pmi.gov\/about\/pmi\u2010annual\u2010report\u20102019. Published 2019. Accessed April 17 2022."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00423-5"},{"issue":"2","key":"e_1_2_11_6_1","article-title":"Clinical pharmacology of artemisinin\u2010based combination therapies","volume":"47","author":"German PI","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70031-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0110-5"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2013.878815"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01700-12"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1527"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181acb4ff"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr596"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12019"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31826ebb5c"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05265-11"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.11-0558"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02716-14"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/11592620-000000000-00000"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky297"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-212"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00015-15"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0581-y"},{"key":"e_1_2_11_24_1","volume-title":"Policy Brief on Single\u2010Dose Primaquine as a Gametocytocide in Plasmodium falciparum Malaria","author":"WHO","year":"2015"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0672-1"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006682"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2009.09-0351"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1716"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30163-4"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.2196\/20904"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cae3b"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03446-8"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15092032"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.778-782.2002"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0092-9"},{"key":"e_1_2_11_36_1","unstructured":"FDA.Examples of clinical inhibitors for P450\u2010mediated metabolisms (for concomitant use clinical DDI studies and\/or drug labeling).https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/drug\u2010development\u2010and\u2010drug\u2010interactions\u2010table\u2010substrates\u2010inhibitors\u2010and\u2010inducers#table3\u20102. Published 2020. Accessed April 17 2022."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.2073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:45:41Z","timestamp":1692805541000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/jcph.2073"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2073","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2022-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}